Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 15 recruiting now early-phase tilt

Oncology: early-phase trial registry

15 of 25 indexed Oncology trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #652 of 28,707 conditions by registered trial count.

25 US clinical trials · 15 currently recruiting · #652 of 28,707 conditions by registered trial count

Oncology: 25 US clinical trials tracked, 15 recruiting.

Oncology is the subject of 25 registered US clinical trials on ClinicalTrials.gov, 15 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is Amgen, running 2 of these trials.

Enrollment posture brief

Registry condition oncology

OPEN 15 | RECR 60% | LATE 1 | EARLY 9 | RANK #652 | SPON 2

Nearest open-share peer: Abuse, Drug (60% recruiting · 5 trials)

Oncology (this)60%Alpha-1 Antitrypsin Deficien48%Alcohol Use40%Acute Lymphocytic Leukemia36%Alcohol-Related Disorders36%
Open-enrollment share among volume-matched conditions near Oncology

Oncology lists 15 open slots (60% of 25 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Oncology on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Oncology is recruiting above its size-band peers.

    15 of 25 indexed trials (60%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Oncology trials is spread across many organizations.

    Amgen accounts for 2 of 25 trials (8%). 23 distinct sponsors appear on at least one study for this condition label.

  3. Typical Oncology enrolment sits around 94 participants.

    Median target enrolment is 94 among the 25 trials that report a genuine target (sentinel values excluded). 13 of those (52%) plan for fewer than 100 participants.

  4. Oncology research is mostly interventional.

    21 interventional and 4 observational studies make up this index (84% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 17Phase 22Phase 41

Open and recent trials

25 total, page 1 of 1

RECRUITING 8,000 participants

The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

UMC Utrecht

NCT04075305

RECRUITING NA 1,020 participants

A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers

University of Rochester

NCT06697600

RECRUITING 600 participants

Autoimmunity After Checkpoint Blockade

Abramson Cancer Center at Penn Medicine

NCT04119713

RECRUITING 500 participants

AIMS Cancer Outcomes Study

Advanced Integrative Medical Science Institute

NCT04495790

RECRUITING 400 participants

xPedite: A Study to Expedite DIPG and DMG Research

xCures

NCT06140719

RECRUITING Phase 1 332 participants

A Study in Patients With Advanced Cancers

BiOneCure Therapeutics

NCT05320588

RECRUITING NA 300 participants

Feasibility and Acceptability of Internet-based Parent-child Interaction Therapy (I-PCIT) in Pediatric Cancer

Johns Hopkins All Children's Hospital

NCT06346782

RECRUITING Phase 1 230 participants

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

Nested Therapeutics

NCT06326411

RECRUITING NA 208 participants

Clinical Alternatives for Reducing Harm Using E-cigarettes

Medical University of South Carolina

NCT07039292

RECRUITING Phase 2 200 participants

RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy

The Hospital for Sick Children

NCT03118986

RECRUITING NA 100 participants

Leading Healthy Eating and Activity Promotion Program

University of Alabama at Birmingham

NCT06868524

RECRUITING Phase 1 94 participants

Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors

Trethera

NCT05055609

RECRUITING Phase 4 40 participants

Effect of Position and Anesthetic Choice in Intraocular Pressure in Robotic GYN (Gynecologic) Oncology Patients

University of Florida

NCT04281017

RECRUITING NA 40 participants

Evaluating the Implementation and Impact of Standard-of-care Delivered Oncology Financial Navigation

University of Alabama at Birmingham

NCT07281287

RECRUITING NA 35 participants

CTNow: A Clinical Trials Education Program for Rural Cancer Patients and Oncology Providers

University of Hawaii

NCT06237816

ACTIVE NOT RECRUITING NA 83 participants

Feasibility Usability & Acceptability Study: Symptom Reporting by Children Adolescents & Young Adults w/Cancer

Stanford University

NCT06824441

ACTIVE NOT RECRUITING NA 63 participants

Radiation Therapy Alone Versus Radiation Therapy Plus Radiofrequency Ablation (RFA)/Vertebral Augmentation

Baptist Health South Florida

NCT04375891

COMPLETED Phase 1 103 participants

AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR

Amgen

NCT00770536

COMPLETED NA 63 participants

The STEPP Study: Sensors To Evaluate Physical Performance

UNC Lineberger Comprehensive Cancer Center

NCT03952767

COMPLETED Phase 2 63 participants

Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)

Amgen

NCT00413283

COMPLETED Phase 1 56 participants

Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function

Gilead Sciences

NCT02521376

COMPLETED NA 38 participants

Mindfulness-Music Intervention for Adolescents and Young Adults With Cancer

Dana-Farber Cancer Institute

NCT03709225

COMPLETED Phase 1 36 participants

A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia

Kartos Therapeutics

NCT02016729

COMPLETED NA 34 participants

EMR Chemotoxicity Risk Calculator To Decrease Chemotherapy Toxicity

Masonic Cancer Center, University of Minnesota

NCT05809557

COMPLETED Phase 1 25 participants

A Study of AMG 820 in Subjects With Advanced Solid Tumors

AmMax Bio

NCT01444404

Phase Distribution

PhaseTrial count
Phase 1 7
Phase 2 2
Phase 4 1

Named interventions

Most-linked intervention names on Oncology records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

AMG 232 Drug
1 trials
Oncology Consultation Other
1 trials
Chemotherapy toxicity tool Other
1 trials
B3: AMG 386 15mg/kg + Topotecan Drug
1 trials
B1: AMG 386 10 mg/kg + Topotecan Drug
1 trials
A3: AMG 386 15mg/kg + Liposomal doxorubicin Drug
1 trials
A1: AMG 386 10 mg/kg + Liposomal doxorubicin Drug
1 trials
AMG 820 Drug
1 trials

US sites by state

Facility locations filed on Oncology trials. A trial with sites in several states counts in each.

Florida 7 trials
California 7 trials
North Carolina 6 trials
Texas 5 trials
Pennsylvania 5 trials
New York 4 trials
Alabama 4 trials
South Carolina 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Oncology page

25 registered trials, 15 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 15 Oncology trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Amgen sponsors the most Oncology trials on record, review their full trial history before evaluating a specific study. See Amgen's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Oncology condition card totals 25 registered trials; most-linked intervention AMG 232; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.